These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 7743511

  • 21. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
    Liebes L, Potmesil M, Kim T, Pease D, Buckley M, Fry D, Cho J, Adler H, Dar K, Zeleniuch-Jacquotte A, Hochster H.
    Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
    [Abstract] [Full Text] [Related]

  • 22. Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.
    Sukhanova A, Grokhovsky S, Zhuze A, Devy J, Pluot M, Oleinikov V, Nabiev I.
    Anticancer Res; 2003 Mar; 23(3B):2609-15. PubMed ID: 12894548
    [Abstract] [Full Text] [Related]

  • 23. Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells.
    Hennequin C, Giocanti N, Balosso J, Favaudon V.
    Cancer Res; 1994 Apr 01; 54(7):1720-8. PubMed ID: 8137287
    [Abstract] [Full Text] [Related]

  • 24. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug.
    Li TK, Houghton PJ, Desai SD, Daroui P, Liu AA, Hars ES, Ruchelman AL, LaVoie EJ, Liu LF.
    Cancer Res; 2003 Dec 01; 63(23):8400-7. PubMed ID: 14679002
    [Abstract] [Full Text] [Related]

  • 25. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.
    Tanizawa A, Kohn KW, Kohlhagen G, Leteurtre F, Pommier Y.
    Biochemistry; 1995 May 30; 34(21):7200-6. PubMed ID: 7766631
    [Abstract] [Full Text] [Related]

  • 26. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
    Tesauro C, Simonsen AK, Andersen MB, Petersen KW, Kristoffersen EL, Algreen L, Hansen NY, Andersen AB, Jakobsen AK, Stougaard M, Gromov P, Knudsen BR, Gromova I.
    BMC Cancer; 2019 Nov 29; 19(1):1158. PubMed ID: 31783818
    [Abstract] [Full Text] [Related]

  • 27. A specific transcriptional response of yeast cells to camptothecin dependent on the Swi4 and Mbp1 factors.
    Lotito L, Russo A, Bueno S, Chillemi G, Fogli MV, Capranico G.
    Eur J Pharmacol; 2009 Jan 28; 603(1-3):29-36. PubMed ID: 19094980
    [Abstract] [Full Text] [Related]

  • 28. Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.
    Sorensen M, Sehested M, Christensen IJ, Larsen JK, Jensen PB.
    Br J Cancer; 1998 Jun 28; 77(12):2152-61. PubMed ID: 9649127
    [Abstract] [Full Text] [Related]

  • 29. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
    Pratesi G, De Cesare M, Carenini N, Perego P, Righetti SC, Cucco C, Merlini L, Pisano C, Penco S, Carminati P, Vesci L, Zunino F.
    Clin Cancer Res; 2002 Dec 28; 8(12):3904-9. PubMed ID: 12473606
    [Abstract] [Full Text] [Related]

  • 30. Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I.
    Wadkins RM, Bearss D, Manikumar G, Wani MC, Wall ME, Von Hoff DD.
    Cancer Res; 2004 Sep 15; 64(18):6679-83. PubMed ID: 15374984
    [Abstract] [Full Text] [Related]

  • 31. SUMO-1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecin.
    Horie K, Tomida A, Sugimoto Y, Yasugi T, Yoshikawa H, Taketani Y, Tsuruo T.
    Oncogene; 2002 Nov 14; 21(52):7913-22. PubMed ID: 12439742
    [Abstract] [Full Text] [Related]

  • 32. In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.
    Pondarré C, Strumberg D, Fujimori A, Torres-León R, Pommier Y.
    Nucleic Acids Res; 1997 Oct 15; 25(20):4111-6. PubMed ID: 9321666
    [Abstract] [Full Text] [Related]

  • 33. Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells.
    Jones CB, Clements MK, Wasi S, Daoud SS.
    Cancer Chemother Pharmacol; 1997 Oct 15; 40(6):475-83. PubMed ID: 9332461
    [Abstract] [Full Text] [Related]

  • 34. Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma.
    Yanase K, Sugimoto Y, Tsukahara S, Oh-Hara T, Andoh T, Tsuruo T.
    Jpn J Cancer Res; 2000 May 15; 91(5):551-9. PubMed ID: 10835501
    [Abstract] [Full Text] [Related]

  • 35. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.
    Tanizawa A, Fujimori A, Fujimori Y, Pommier Y.
    J Natl Cancer Inst; 1994 Jun 01; 86(11):836-42. PubMed ID: 8182764
    [Abstract] [Full Text] [Related]

  • 36. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants.
    Jansen WJ, Zwart B, Hulscher ST, Giaccone G, Pinedo HM, Boven E.
    Int J Cancer; 1997 Jan 27; 70(3):335-40. PubMed ID: 9033637
    [Abstract] [Full Text] [Related]

  • 37. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression.
    Takebayashi Y, Goldwasser F, Urasaki Y, Kohlhagen G, Pommier Y.
    Clin Cancer Res; 2001 Jan 27; 7(1):185-91. PubMed ID: 11205907
    [Abstract] [Full Text] [Related]

  • 38. Janus-activated kinases and signal transducer and activator of transcription control tumor growth response to camptothecin in human colon cancer cells.
    Yun HJ, Kim SY, Kwon YY, Kim CH, Kang CM, Kim EJ.
    Cancer Biol Ther; 2010 Aug 15; 10(4):354-61. PubMed ID: 20534983
    [Abstract] [Full Text] [Related]

  • 39. Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations.
    Urasaki Y, Takebayashi Y, Pommier Y.
    Cancer Res; 2000 Dec 01; 60(23):6577-80. PubMed ID: 11118036
    [Abstract] [Full Text] [Related]

  • 40. Pharmacological determinants of 9-aminocamptothecin cytotoxicity.
    Li ML, Horn L, Firby PS, Moore MJ.
    Clin Cancer Res; 2001 Jan 01; 7(1):168-74. PubMed ID: 11205905
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.